13 September 2019 in Epidemiology and Vaccinal Prevention
Relevance.Bronchial asthma is widespread in the world, according to WHO estimates, 235 million people suffer from it. In Russia, according to official figures, 1.3 million cases of bronchial asthma have been reported. Domestic experts reasonably believe that these data are underestimated at least 4 times. Considering that patients with bronchial asthma undergo significant changes in the immune system and are especially difficult to tolerate respiratory and other infectious diseases, determining the effect of vaccination on the clinical course of bronchial asthma is very important. The purpose of the review is to show how vaccinations against pneumococcal infection and influenza affect the condition of patients with bronchial asthma.Conclusion.Features of formation of protective immunity at various schemes of immunization against pneumococcal infection are analyzed. In patients with bronchial asthma, the justification of the vaccination scheme with the advantage of the priority administration of conjugated polysaccharide vaccine with the subsequent introduction of a polysaccharide pneumococcal vaccine after 8 weeks is given. Vaccination against pneumococcal infections has led to the elimination of sputum S. рneumoniae. In vaccination against pneumococcal infection, there was an improvement in the level of disease control, which was confirmed by the ACQ-5 test-a decrease in the indicator from 2 [1,5;1,8;3] points (lack of asthma control) to 0,6 [0;1] points (asthma control) during the year of observation, p < 0,001. Vaccination against influenza in patients with bronchial asthma leads to a decrease in the frequency and duration of exacerbations, there is a decrease in the level of markers of systemic inflammation. Combined vaccination against influenza and pneumococcal infection is not accompanied by a reliable difference in tolerability in comparison with monovaccination only against pneumococcal infection or influenza.
3 May 2024 in Epidemiology and Vaccinal Prevention
The considerable success of vaccination against the new coronavirus infection, which has led to a decrease in morbidity and mortality in adults and children, requires the study of the problem of revaccination against SARS-CoV-2. The pathogenic properties of the virus and its unpredictable mutations continue to support an unfavorable epidemic situation in different regions of the world. Revaccination regimens against SARS-CoV-2 are being developed in different countries and populations based on epidemiological indications. The issue of introducing vaccination against a new coronavirus infection into national vaccination calendars for adults and children is debatable and requires further study.
11 March 2025 in Clinical Medicine (Russian Journal)
A rare case of fatal outcome in Celen–Gellerstedt syndrome with the development of microhemorrhages in the lungs after reinfection with SARS-CoV-2 is presented. The morphological changes in lung tissue and their correlation with clinical, laboratory, and instrumental study data are described. Multiple hemorrhages with areas of pneumonia were found in the lung tissue. The interalveolar septa exhibited fibrinoid disorganization, diffuse infiltration, and scattered multinucleated cells containing hemosiderin. A distinctive feature of this case is that the fatal outcome occurred at a young age, with no thickening of the alveoli, fibrosis of lung tissue, right heart hypertrophy, or somatic pathology, but with pronounced morphological changes in the form of fibrinoid disorganization of the vessel walls, diffuse cellular infiltration, and significant hemorrhagic exudate in the alveolar lumens. Multiple hemorrhages with an abundance of macrophages and hemosiderin granules were observed, and cells in the interalveolar septa showed karyolysis. Ruptures of small and medium-sized pulmonary vessels and small thrombi in some of them were noted. Thus, the hereditary insufficiency of elastic fibers in the small and medium-sized pulmonary vessels, characteristic of Celen–Gellerstedt syndrome, likely contributed to their dilation, increased permeability, blood stasis, ruptures, and hemorrhages in lung tissue. It is particularly noteworthy that small thrombotic masses were identified specifically in these vessels. The trigger was reinfection with SARS-CoV-2.
21 October 2022 in Pediatria. Journal named after G.N. Speransky
CHCheboksary Cheboksary City Children’s Clinical Hospital
Cheboksary Cheboksary City Children’s Clinical Hospital
The new coronavirus infection pandemic has had a major impact on public health. In order to decrease the volume of severe cases the mass vaccination is needed. The purpose of the study was to analyze the results of immunization of children against COVID-19. Materials and methods of the research: a single-center cohort prospective continuous study of the results of the COVID-19 vaccination in children and adolescents was carried out in Feb. - Mar. 2022. The research included 385 children and adolescents aged 12 to 17 years old divided into 2 groups: children aged 12 to 14 and adolescents aged 15 to 17 y/o. The combined vector-based vaccine “Gam-COVID-Vac-M” with two stages and 21 days interstage interval was used. The general and local reactions were studied for 42 days in both groups. Results: the impaired health and local reactions after the 1st stage of vaccination were statistically significantly more common in girls aged 12 to 14 y/o: 8 (16.0%) compared to 2 (2.9%) boys (p=0.0012). Among adolescents aged 15 to 17 y/o statistically significant differences between boys and girls were recorded after the 2nd stage of vaccination in the forms of: violation of well-being: in 36 (20.5%) boys and 37 (40.6%) girls (p=0.007); subfebrile condition in the 1st day after the vaccination in 33 (18.7%) boys and 36 (39.5%) girls (p=0.004). Conclusion: despite the insufficient number of cases studied and the impossibility for the researcher to control all the key parameters that contribute to the assessment of the tolerability of the 1st and the 2nd stages of vaccination, the results indicate the good tolerability and safety of vaccination against COVID-19 in children and adolescents. The results obtained indicate the statistically significant differences between the group of children aged 12 to 14 y/o, in whom 98 (83.1%) vaccinated had an uncomplicated course of the early post-vaccination period, compared to adolescents aged 15 to 17 y/o, where only 194 (72.7%) had an uncomplicated course of the early post-vaccination period (p=0.029).